

Print Name		Signature	Date	
<ul> <li>Contraindications: Pu</li> <li>Advice on how to apple</li> </ul>	lmonary oedema, oedema, Leg/foot i.e. dermatitis, ext y correctly and rec	Peripheral vascular disea ulceration, Pressure sore reme deformity; acute st ommended wear should		
VTE prophylaxis with LMWH <sup>4,5</sup> (Dalteparin LMWH of choice in NHS Ayrshire and Arran)				
Elective ward admission (on evening before procedure)	Moderate Risk: High Risk:	Dalteparin 2500 units Dalteparin 5000 units		
Day surgery / Same day admissions to general ward	Moderate Risk: High Risk: Or	Dalteparin 2500 units 1- 8-12 hours post-op if ha	peri-op and Dalteparin 2500 units post-op 2 hours pre-op and Dalteparin 2500 units remostasis established peri-op and Dalteparin 5000 units post-op	
Emergency admissions (at 10 pm day of admission)	Moderate Risk: High Risk:	Dalteparin 2500 units Dalteparin 5000 units		
Maintenance dose options (Emergency and elective) Once daily at 6pmModerate Risk: Dalteparin 5000 unitsContinue Dalteparin until discharge Extended prophylaxis can be considered for patients with additional predisposing thrombosis risk factors				
<ul> <li>General measures:</li> <li>Keep patients adequately hydrated</li> <li>Early mobilisation and leg exercises should be encouraged</li> <li>Provide the Reducing the risk of deep vein thrombosis (DVT) information leaflet to all patients</li> <li>Reassess VTE risk and bleeding risk, every 48 – 72 hours or sooner if patient's condition changes</li> <li>Document all assessments and any changes in medical notes</li> <li>Document in medical notes if patient is excluded form VTE prophylaxis</li> <li>Alert GP and district nursing staff if patient discharged with extended prophylaxis</li> </ul>				
<ul> <li>References: <ol> <li>Scottish Intercollegiate Guidelines Network (SIGN) Guideline 122 (2010). Prevention and Management of Venous Thromboembolism: A National Clinical Guideline. Edinburgh: SIGN December 2010</li> <li>Department of Health 2010. Risk Assessment for Venous Thromboembolism (VTE). Accessed at <a href="http://www.dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_088215_on_27/9/12">http://www.dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_088215_on_27/9/12</a>, now available at: <ul> <li><a href="http://www.dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_088215_accessed">http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publicationsandstatistics/Publications/Publicationsandstatistics/Publications/Publicationsandstatistics/Publications/Publicationsandstatistics/Publications/Publications/Publicationsandstatistics/Publications/Publications/Publicationsandstatistics/Publications/Publications/Publications/Publications/Publicationsandstatistics/Publications/Publications/Publications/Publications/Publications/Publications/Publicationsandstatistics/Publications/Pu</a></li></ul></li></ol></li></ul>				

I confirm that the risks of deep vein thrombosis and pulmonary embolus have been discussed with me. I wish to decline the recommended prophylaxis.

Disclaimer if declining VTE prophylaxis